Investigating factors that influence prescribing of disease modifying treatments for MS

Image shows prescriptions piled on a desk

David French

University of Manchester

£71,204

About the project

We know that not everyone with relapsing MS has access to potentially beneficial disease modifying treatments (DMTs). In fact, prescribing of DMTs in the UK is much lower than a lot of European countries. We've also found that access to treatment varies from region to region within the UK through our Treat Me Right campaign.

Our researchers are working to understand what factors affect prescribing of DMTs in the UK. They will do this by interviewing neurologists as well as MS specialist nurses. They will then launch a UK-wide survey to investigate the different attitudes to prescribing.

How will it help people with MS?

We will use this research to campaign for policy and service changes that address the most commonly reported barriers to prescribing of DMTs. This will could result in improved access to DMTs across the whole of the UK.

The difference you can make

It is only with support like yours we can fund projects like this and help people with MS have the best possible experience with their healthcare professionals.

The next research breakthrough is in reach

Your donation will help stop MS.

  • Please enter an amount

    Our minimum donation is £2, please enter a different amount.

£10could buy vital lab supplies for MS researchers, helping them find ways to stop MS faster

£20could pay for lab equipment like petri dishes to grow bacteria important for studying the genetics of MS

£30could process one blood sample, giving us crucial information about genes that could lead to treatment breakthroughs

Every penny you give really does take us a step closer to stopping MS. Your donation will make a difference.

Donate now

  • Please enter an amount

    Our minimum donation is £2, please enter a different amount.

£10a month could pay for lab equipment like microscope slides to study the building blocks of MS

£20a month could pay for lab equipment like petri dishes to grow bacteria important for studying genetics

£30a month could process a blood sample to help us understand what causes MS, so we can stop it in its tracks

Your regular donation means we can keep funding world class MS research with confidence. Together we will stop MS.

Donate now
Young girl in hospital ward talking to male nurse

You may also be interested in

Image shows a stethoscope on top of research papers

Positive results for clinical trial in progressive MS

Researchers in the US have proclaimed their initial test of ibudilast for MS a success.

Read more on the test of ibudilast
Photo shows MS Society Trishna Bharadia at the launch of the Song Cycle album

Dealing with uncommon symptoms and side effects

Trishna writes about experiencing unexpected symptoms, associated with her MS, including chronic urticaria (“hives”) and angiodema (deep tissue swelling)

Read Trishna's blog about unusual symptoms
ocrelizumab infusion drip

NICE approves ocrelizumab for early primary progressive MS

Today the National Institute for Health and Care Excellence (NICE) has approved ocrelizumab as the first treatment on the NHS for adults with early primary progressive MS.

Read about NICE's approval of ocrelizumab